Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer

Merck’s Keytruda may not have qualified as a second- or third-line treatment of triple negative breast cancer, but the PD-1 inhibitor is showing promise for the first-line setting in a Phase III trial.